Published • loading... • Updated
Bora Navigates A Transitional 1Q26 And Sets A Strong Foundation For Rest Of The Year
The company said the deal would add a US$122.5 million biologics site and lift its 12-month rolling backlog to about US$375 million.
Summary by Hastings Tribune
7 Articles
7 Articles
Hastings Tribune+4 Reposted by 4 other sources
Bora Navigates A Transitional 1Q26 And Sets A Strong Foundation For Rest Of The Year
Transformational Acquisitions Expected to Contribute to Long Term Growth Starting 2Q26
·Nebraska, United States
Read Full Article
Bora navigates transitional Q1 2026, sets foundation for rest of year
HONG KONG SAR - Media OutReach Newswire – 13 May 2026 – Bora Pharmaceuticals ("Bora"; TWSE: 6472; OTCQX: BORAY) today announced its financial results and operational highlights for 1Q2026 and provides full year outlook. 1Q26 Business and Financial Highlights The Company reported 1Q26 revenues of NT$4,001 million, down 17.68% sequentially, with basic EPS of NT$0.21. Gross margin stabilized quarter-over-quarter. The quarter reflected temporary sl…
Coverage Details
Total News Sources7
Leaning Left1Leaning Right1Center1Last UpdatedBias Distribution34% Left, 33% Center, 33% Right
Bias Distribution
- 34% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
34% Left
L 34%
C 33%
R 33%
Factuality
To view factuality data please Upgrade to Premium
